Drug firmEmcure Pharmaceuticals on Wednesday has launched its genericmetastaticbreastcancertreatment drug under the brand name Eribilin inIndia.

The product is a generic version ofEisaiPharmaceutical'scancerdrug sold under the brand name, Halaven,Emcure Pharmaceuticals has said in a statement.

“Breastcanceris the most common type of cancer affecting women inIndiaand its incidence is on the rise. Currently availabletreatment fortriple negativebreast cancerinIndiais out of reach of most patients due to its high cost,” Emcure PharmaceuticalsBusiness Strategy & SpecialtyBusiness PresidentSainath Iyersaid.

Emcure's Eribilin will change this scenario by offering the drug at a reasonable price to the patients in India, he added.

The company will manufacture the product at its plant at Hinjewadi in Pune and market it at a cost which will be approximately 40 per cent less than the innovator brand, Emcure Pharmaceuticals said.

"The drug would currently be marketed in India, however Emcure plans to register the brand in international markets as well, wherever the drug is about to go off-patent," the company said.

The company will manufacture the product at its plant at Hinjewadi in Pune and market it at a cost which will be approximately 40 per cent less than the innovator brand.